By Fineline Cube Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that the first patient has been dosed in a Phase I clinical study of BAT8006, an in-house developed antibody drug conjugate (ADC) targeting folate receptor alpha (FRα), for advanced solid tumors. The multi-center, open-label trial will assess the drug’s safety, tolerability, and preliminary efficacy.
Study Details
The Phase I study aims to determine the recommended Phase II dosage for BAT8006. The trial will enroll patients with advanced solid tumors, focusing on those with high FRα expression, such as ovarian, lung, and breast cancers.
Drug Profile
BAT8006 combines a recombinant humanized anti-FRα antibody with a topoisomerase I inhibitor. Preclinical studies demonstrated strong anti-tumor efficacy, stability, and a favorable safety profile, positioning it as a potential best-in-class therapy. FRα is overexpressed in various solid tumors but has limited expression in normal tissues, making it a promising target for ADCs.-Fineline Info & Tech